Taking stock of the drug industry, from the lab to the medicine chestJanuary 20, 2026Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer JUSTIN TALLIS/AFP via Getty Images STAT+ | GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal The centerpiece of the deal is ozureprubart, which is in Phase 2 development as a prophylactic treatment for food allergies. By Andrew Joseph STAT+ | Florida proposes cutting eligibility for an AIDS drug program, causing panic "This is medical malpractice," said Carl Schmid, who heads the HIV+Hepatitis Policy Institute, an advocacy group. By Ed Silverman STAT+ | What's in Congress' sweeping health care deal: PBM reform, telehealth, science funding Appropriations bill would give HHS $116.8 billion, a modest increase over 2025 but $33 billion more than the Trump administration requested. By John Wilkerson and Daniel Payne Adobe/STAT STAT+ | Opinion: Excitement and wariness as FDA shifts to much more flexible cell and gene therapy oversight The new "flexible" CGT oversight system could accelerate development — but it comes with risks for the whole field, and even the FDA itself. By Paul Knoepfler STAT+ | Corvus pill shows promise in early-stage eczema trial A number of companies are developing eczema treatments that aim to outperform the market's current leader, the blockbuster Dupixent. By Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2026, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments